Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C.E.R.A versus darbepoetin alfa for maintenance treatment of anemia in hemodialysis patients with chronic kidney disease
2005-004510-33Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta and darbepoetin alfa in Uraemic Anaemia (2 arms), sponsored by Roche. Primary endpoint: Hemoglobin response maintenance during weeks 50 to 53. Started Sep 2006; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin betadarbepoetin alfa
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on 2005-004510-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004510-33.